Akero Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Reuters05-10

* Akero Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on May 10 for the period ending June 30 2024

*

* LSEG's mean analyst estimate for Akero Therapeutics Inc is for a loss of 97 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts had fallen by about 5.0% in the last three months.

* Wall Street's median 12-month price target for Akero Therapeutics Inc is $50.00, above its last closing price of $20.80.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Mar. 31 2024 -0.96 -0.95 -0.90 Beat 5.5

Dec. 31 2024 -0.91 -0.86 -0.99 Missed -14.9

Sep. 30 2023 -0.69 -0.68 -0.71 Missed -4.2

Jun. 30 2023 -0.62 -0.63 -0.60 Beat 4.5

Mar. -0.66 -0.67 -0.55 Beat 18.2

31 2023

Dec. 31 2022 -0.81 -0.80 -0.49 Beat 38.6

Sep. 30 2022 -0.71 -0.74 -0.92 Missed -24.7

Jun. 30 2022 -0.79 -0.86 -0.77 Beat 10

This summary was machine generated May 10 at 15:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434684878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-10 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2434684878","market":"us","top_or_hot":-1,"title":"Akero Therapeutics Inc    expected to post a loss of 97 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Inc     is expected to show no change in quarterly revenue when it reports  results on May 10 for the period ending June 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is for a loss of 97 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts had fallen by about 5.0% in the last three months. </p><p>   * Wall Street's median 12-month price target for Akero Therapeutics Inc is $50.00, above its last closing price of $20.80. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Mar. 31 2024  -0.96       -0.95      -0.90     Beat    5.5</p><p>Dec. 31 2024  -0.91       -0.86      -0.99     Missed  -14.9</p><p>Sep. 30 2023  -0.69       -0.68      -0.71     Missed  -4.2</p><p>Jun. 30 2023  -0.62       -0.63      -0.60     Beat    4.5</p><p>Mar.        -0.66       -0.67      -0.55     Beat    18.2</p><p>31 2023                                                </p><p>Dec. 31 2022  -0.81       -0.80      -0.49     Beat    38.6</p><p>Sep. 30 2022  -0.71       -0.74      -0.92     Missed  -24.7</p><p>Jun. 30 2022  -0.79       -0.86      -0.77     Beat    10</p><p>This summary was machine generated May 10 at 15:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero Therapeutics Inc    expected to post a loss of 97 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero Therapeutics Inc    expected to post a loss of 97 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-10 23:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Akero Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on May 10 for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Akero ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2434684878","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434684878","pubTimestamp":1715353755,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Akero Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on May 10 for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Akero Th","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AKRO":"Akero Therapeutics"},"translate_title":"Akero Therapeutics Inc.预计每股亏损97美分——收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1},"content_text":"* Akero Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on May 10 for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Akero Therapeutics Inc is for a loss of 97 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts had fallen by about 5.0% in the last three months.    * Wall Street's median 12-month price target for Akero Therapeutics Inc is $50.00, above its last closing price of $20.80. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Mar. 31 2024  -0.96       -0.95      -0.90     Beat    5.5Dec. 31 2024  -0.91       -0.86      -0.99     Missed  -14.9Sep. 30 2023  -0.69       -0.68      -0.71     Missed  -4.2Jun. 30 2023  -0.62       -0.63      -0.60     Beat    4.5Mar.        -0.66       -0.67      -0.55     Beat    18.231 2023                                                Dec. 31 2022  -0.81       -0.80      -0.49     Beat    38.6Sep. 30 2022  -0.71       -0.74      -0.92     Missed  -24.7Jun. 30 2022  -0.79       -0.86      -0.77     Beat    10This summary was machine generated May 10 at 15:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434684878"}